Response Biomedical (RPBIF) 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 01, 2016
Document Information [Line Items]
Entity Registrant Name	RESPONSE BIOMEDICAL CORP
Entity Central Index Key	806,888
Trading Symbol	rpbif
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		10,917,269
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - CAD CAD in Thousands		Jun. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents		CAD 1,580	CAD 2,511
Trade receivables, net		442	466
Other receivables		79	100
Inventories [note 5]		2,195	1,819
Prepaid expenses and other		667	182
Total current assets		4,963	5,078
Long-term prepaid expenses		93	93
Restricted deposits [note 8]		317	901
Property, plant and equipment		5,330	5,689
Total assets		10,703	11,761
Current liabilities
Accounts payable and accrued liabilities [note 6]		3,793	3,297
Term loan - current portion [note 7]		720	801
Lease inducements - current portion [note 8]		169	169
Repayable leasehold improvement allowance - current portion [note 8]	[1]	543	514
Deferred revenue		1,530	1,311
Warrant liability [notes 4 and 9]		964	301
Total current liabilities		7,719	6,393
Term loan [note 7]			357
Lease inducements [note 8]		943	1,028
Repayable leasehold improvement allowance [note 8]		4,415	4,694
Liabilities		13,077	12,472
Shareholders' deficit
Common shares [note 9]		105,010	104,314
Additional paid-in capital [note 9]		15,596	15,384
Deficit		(122,980)	(120,409)
Total shareholders' deficit		(2,374)	(711)
Total liabilities and shareholders' deficit		CAD 10,703	CAD 11,761
[1]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three month period ended March 31, 2016 amounted to $123,000 [2015 - $110,000]. Interest payments for the three month period ended March 31, 2016 amounted to $142,000 [2015 - $155,000].

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - CAD CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
REVENUE
Product sales [note 12]	CAD 1,265	CAD 3,563	CAD 3,356	CAD 6,834
Collaborative revenue [note 10]	56	703	169	972
Total revenue	1,321	4,266	3,525	7,806
Cost of sales [notes 5, 9, and 11]	799	2,120	1,976	4,296
Gross profit	522	2,146	1,549	3,510
EXPENSES [notes 9 and 11]
Research and development	420	621	981	1,434
General and administrative	698	681	1,460	1,356
Sales and marketing	321	469	817	1,133
Total operating expenses	1,439	1,771	3,258	3,923
OTHER EXPENSES (INCOME)
Interest expense and amortization of deferred financing costs and debt discount [note 7]	177	225	368	460
Other expense/(income)	2	(19)	30
Foreign exchange loss/(gain)	3	21	(199)	134
Unrealized loss on revaluation of warrant liability	223	150	663	95
Total other expenses	405	377	862	689
Net loss and comprehensive loss for the period	CAD (1,322)	CAD (2)	CAD (2,571)	CAD (1,102)
Loss per common share – basic and diluted [note 9] (in Canadian Dollar per share)	CAD (0.13)	CAD 0	CAD (0.26)	CAD (0.11)
Weighted average number of common shares outstanding – basic and diluted [note 9] (in shares)	10,061,524	9,889,028	9,993,390	9,832,274

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficit (Unaudited) - CAD CAD in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2014	9,759,560
Balance at Dec. 31, 2014	CAD 104,124	CAD 15,241	CAD (120,259)	CAD (894)
Net Income (Loss) Attributable to Parent			(150)	(150)
Net shares issued upon conversion of restricted share units (in shares)	165,696
Net shares issued upon conversion of restricted share units	CAD 190	(190)
Stock-based compensation expense		218		218
Restricted share units		115		115
Balance (in shares) at Dec. 31, 2015	9,925,256
Balance at Dec. 31, 2015	CAD 104,314	15,384	(120,409)	(711)
Net Income (Loss) Attributable to Parent			(2,571)	(2,571)
Net shares issued upon conversion of restricted share units (in shares)	99,155
Net shares issued upon conversion of restricted share units	CAD 97	(97)
Stock-based compensation expense		135		135
Restricted share units		100		100
Balance (in shares) at Jun. 30, 2016	10,917,269
Balance at Jun. 30, 2016	CAD 105,010	15,596	(122,980)	(2,374)
Private placement, net of issue costs (in shares)	892,858
Private placement, net of issue costs	CAD 599			599
Deferred share units		CAD 74		CAD 74

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - CAD	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
OPERATING ACTIVITIES
Net Income (Loss) Attributable to Parent	CAD (2,571,000)	CAD (1,102,000)
Add (deduct) items not involving cash:
Depreciation of property, plant and equipment	495,000	505,000
Amortization of deferred lease inducements	(85,000)	(85,000)
Amortization of deferred financing costs	27,000	49,000
Amortization of discount on debt	16,000	29,000
Stock-based compensation	135,000	105,000
Unrealized loss on revaluation of warrant liability	663,000	95,000
Unrealized foreign currency transactions	(143,000)	152,000
Changes in non-cash working capital:
Trade receivables	26,000	(1,180,000)
Other receivables	21,000	(30,000)
Inventories	(376,000)	(669,000)
Prepaid expenses and other	(11,000)	20,000
Accounts payable and accrued liabilities	155,000	1,232,000
Deferred revenue	205,000	1,000
Cash used in operating activities	(1,442,000)	(878,000)
INVESTING ACTIVITIES
Purchase of property, plant and equipment	(26,000)	(353,000)
Reduction of restricted cash	584,000
Cash generated from (used in) investing activities	558,000	(353,000)
FINANCING ACTIVITIES
Repayment of repayable leasehold improvement allowance	(250,000)	(224,000)
Repayment of term loan	(419,000)	(195,000)
Proceeds from issuance of common shares, net of share issue costs	599,000
Cash provided used in financing activities	(70,000)	(419,000)
Effect of exchange rate changes on cash and cash equivalents	23,000	15,000
Decrease in cash and cash equivalents during the period	(931,000)	(1,635,000)
Cash and cash equivalents, beginning of period	2,511,000	3,221,000
Cash and cash equivalents, end of period	CAD 1,580,000	CAD 1,586,000

Note 1 - Description of Busines

Note 1 - Description of Business	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. DESCRIPTION OF BUSINESS Response Biomedical Corp. (“Response” or the “Company”) was incorporated on August 20, 1980 under the predecessor to the Business Corporations Act (British Columbia). The Company’s wholly owned US subsidiary, Response Point of Care Inc., was incorporated on November 9, 2012 in the State of Delaware. The Company is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical point of care (POC), laboratory and on-site environmental testing markets. POC and on-site diagnostic tests (or assays) are simple, non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. Since 1996, the Company has developed and commercialized a proprietary diagnostic system called RAMP ® The RAMP ® ® ®

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Going Concern Uncertainty	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2. BASIS OF PRESENTATION AND GOING CONCERN UNCERTAINTY These unaudited interim consolidated financial statements have been prepared by management in Canadian dollars in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required to be presented for complete financial statements. The accompanying unaudited consolidated financial statements reflect, in the opinion of management, all adjustments (which include reclassifications and normal recurring adjustments) necessary for a fair presentation of the results for the interim periods presented. The accompanying consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year then ended. The consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2015 and filed with the United States Securities and Exchange Commission (“SEC”) on March 24, 2016. Going Concern Uncertainty The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. During the six month period ended June 30, 2016, the Company incurred a net loss of $2.6 million and negative cash flows of $0.9 million. As of June 30, 2016, the Company had a cash balance of $1.6 million, an accumulated deficit of $123.0 million, a shareholders’ deficit of $2.4 million, and a working capital deficit of $2.8 million. In addition, the Company has various operating leases and purchase commitments for inventory (refer to note 11). Included in current liabilities is a warrant liability in the amount of $964,000 that is required to be measured at fair value and is presented as a current liability in accordance with Accounting Standards Codification Topic 815 – Derivatives and Hedging (“ASC 815”). Each warrant may only be exercised on a net cashless exercise basis and no warrant may be exercised at a time when the exercise price equals or exceeds the current market price meaning the potential settlement of any warrant does not require any cash disbursement. Without taking into account the warrant liability mentioned above, current liabilities exceed current assets by $1.8 million. Sales to the Company’s former national distributor in China represented 31% of product sales during the first half of 2016 and were 79% lower than sales to the same distributor in the comparable six month period in 2015. The purchases of products from the Company in the first six months of 2016 were in satisfaction of rebates that were accrued in 2015. The Company received the payment for these products in the first half of 2015 and therefore, no additional cash was received during 2016 for these products. No returns of the products purchased by the former national distributor are either expected or permitted under the terms of its distribution agreement. The Company converted this distributor’s national distribution rights to non-exclusive effective March 3, 2016. The Company has now contracted with new distributors in China, including Shanghai Runda Medical Technology Co., Ltd. (“Runda”), to attempt to improve our current sales levels. The Company announced on June 16, 2016 that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with 1077801 B.C. Ltd., a company owned by OrbiMed Asia Partners, LP, OrbiMed Private Investments III, LP and OrbiMed Associates III, LP and Runda pursuant to which 1077801 B.C. Ltd. will acquire all of the issued and outstanding common shares of the Company for cash consideration of $1.12 per share (except in the case of certain rollover shareholders who will instead receive shares of 1077891 B.C. Ltd. on a 1 to 1 basis). This transaction is subject to customary approvals, including but not limited to, the approval of at least 66 2/3% of the votes cast in person or by proxy at a Special Meeting and the approval of a majority of the shareholders’ votes cast in person or by proxy at the Special Meeting excluding shareholders whose votes may not be included pursuant to Multilateral Instrument 61-101. In addition, closing of this transaction is subject to the satisfaction of a number of conditions, including the receipt of certain regulatory, court and stock exchange approvals in addition to foreign approvals that are required. Following the closing of this transaction, the Company intends to de-list from the Toronto Stock Exchange (“TSX”). Concurrent, with the above transaction, the Company entered into subscription agreements to undertake a non-brokered private placement financing of up to 1,785,716 common shares of the Company (the “Private Placement”) at a price of U.S. $0.56 per share for total gross proceeds of approximately U.S. $1,000,000. Pursuant to the Private Placement, Response has entered into subscription agreements with OrbiMed, where OrbiMed funds will subscribe for 892,858 Response Common Shares for total gross proceeds to the Company of approximately U.S. $500,000, and with Runda where Runda will subscribe for 892,858 Response Common Shares for total gross proceeds to the Company of approximately U.S. $500,000. The first tranche of U.S. $500,000 was closed on June 17, 2016 with the OrbiMed funds. The second tranche has not been completed yet. To address the expected near term reduction in product sales in China during this transition period and the resulting significant deterioration of the Company’s near term cash position, in addition to the Private Placement, the Company has implemented several cash conservation and cost reduction initiatives including reducing staff levels and delaying certain research and development projects to extend its available cash resources. While the Company is pursuing these various initiatives, there is no assurance that these efforts will allow the available cash resources to be sufficient to fund the Company’s operations. The ability of the Company to continue as a going concern is uncertain and dependent on the Company’s ability to complete the Arrangement Agreement, obtain additional financing, earn collaboration milestones and/or achieve sustained cash flow positive operations. Management has financed operations, thus far, through a series of equity financings, debt financing, and collaborative arrangements. The Company has received milestones totaling US$3.0 million to date from a collaborative agreement with Hangzhou Joinstar Biomedical Technology Co., Ltd. the (“Joinstar Agreements”) and is eligible to receive a further US$0.8 million from the last development milestone during the remaining project period. In addition, under the terms of a Supply Agreement with Joinstar, Response will receive a guaranteed US$1.78 million in revenue-based payments over the first five years of commercialization of the co-developed assays. The Company is striving to meet its ongoing cash needs through continued efforts to improve sales in China and other markets, reduce costs and otherwise conserve cash, and raise additional financing through the private placement mentioned above. Without additional financing, the Company’s current cash may not be sufficient to allow the Company to continue as a going concern beyond the third quarter of 2016. Management believes that additional financing along with a combination of some or all of the various cost reduction, cash conservation, sales and marketing initiatives, and completion of our collaboration with Joinstar, including short term out of the ordinary cash management measures, will be required to meet its anticipated short term cash requirements. Due to the Company’s history of losses, recent significant decreases in China product sales, and current major transition of distributors in China, there is substantial doubt over the Company’s ability to continue as a going concern as it is dependent on obtaining additional financing and achieving profitable operations, the outcomes of which cannot be predicted at this time. The consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Note 3 - Recent Accounting Pron

Note 3 - Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	3. RECENT ACCOUNTING PRONOUNCEMENTS Newly Adopted Accounting Pronouncements In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”). ASU 2015-03 was issued to simplify the presentation of debt issuance costs. The guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by these amendments. This guidance should be applied on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The adoption of this newly issued guidance resulted in the reclassification of the previously recorded Deferred Debt Financing Costs (both current and long term), which were previously included under the assets section of the consolidated balance sheet, as a deduction of the Term loan (both current and long term) on the consolidated balance sheet. Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (Topic 606) (“ASU 2014-09”), which supersedes the revenue recognition requirements in Accounting Standards Codification 605, “Revenue Recognition.” ASU 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts , including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. On July 9, 2015, the FASB decided to delay the effective date of the new standard by one year. ASU 2014-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. We are evaluating the impact of adopting this pronouncement. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” (Topic 330) (“ASU 2015-11”), which amends the guidelines for the measurement of inventory. Under the amendments, an entity should measure inventory valued using a first-in, first-out or average cost method at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company has not chosen early adoption for this ASU and is currently evaluating the impact of adopting this pronouncement. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 2015-40) (“ASU 2014-15”). ASU 2014-15 provides guidance to U.S. GAAP about management’s responsibility to evaluate whether there is a substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. This new rule requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles currently in the U.S. auditing standards. Specifically, ASU 2014-15 (1) defines the term substantial doubt, (2) requires an evaluation of every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires an express statement and other disclosures when substantial doubt is not alleviated, and (5) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This guidance is effective for annual periods ending after December 15, 2016 . In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires lessees to put most leases on their balance sheets as a liability for the obligation to make lease payments and as a right-of-use asset, but recognize expenses on the income statements in a manner similar to today’s accounting. The guidance also eliminates the current real estate-specific provisions for all entities. This guidance is effective for annual period beginning after December 15, 2018. Early adoption is permitted for all entities. The Company has not chosen early adoption for this ASU and is currently evaluating its effect on the Company’s consolidated financial statements.

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (“exit price”) in an orderly transaction between market participants at the measurement date. Fair value measurements of financial instruments are determined by using a fair value hierarchy that prioritizes the inputs to valuation techniques into three levels according to the relative reliability of the inputs used to estimate the fair values. The three levels of inputs used to measure fair value are as follows: Level 1 – Unadjusted quoted prices in active markets for identical financial instruments; Level 2 – Inputs other than quoted prices that are observable for the financial instrument either directly or indirectly; and Level 3 – Inputs that are not based on observable market data. In determining fair value measurements, the Company uses the most observable inputs when available. For certain of the Company’s financial instruments, including cash and cash equivalents, trade receivables, other receivables, and accounts payable and accrued liabilities the carrying amounts approximate fair values due to their short-term nature. The carrying value of the restricted deposits approximates its fair value due to the nature of the cash deposit. The fair value of the term loan approximates its carrying value as the effective interest rate in the term loan with Silicon Valley Bank ("SVB") approximates the current market rate for the term loan. The fair value of the repayable leasehold improvement allowance approximates its carrying value as the fixed interest rate of 11% is considered to approximate the current market rate. The fair value hierarchy level at which a financial instrument is categorized is determined on the basis of the lowest level input that is significant to the fair value measurement (in thousands): Financial Instrument s carried at fair value as of June 30 , 201 6 Level 1 Level 2 Level 3 Total Liabilities $ $ $ $ Warrant Liability - - 964 964 As of June 30, 2016, the warrant liability is recorded at its fair value of $1. 0 million. The Company reassesses the fair value of the common stock warrants at each reporting date utilizing a Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price volatility, contractual term of the warrant, and risk-free interest rate (refer to note 9[g]). The computation of expected volatility is based on the historical volatility of the Company’s stock. A small change in the estimates used in the Black-Scholes pricing model may have a relatively large change in the estimated valuation of the common stock warrants. The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the six month period ended June 30, 2016 (in thousands): Balance at December 31, 201 5 Unrealized loss Exercise of Warrants Balance at June 30, 201 6 Warrant Liability 301 663 - 964 Quantitative information about unobservable inputs used in Level 3 fair value measurements is presented below: Valuation Technique Unobservable Input As at June 30, 201 6 As at December 31, 201 5 Warrant Liability Option Model Stock Price Volatility 124 % 128 % A 5% increase or decrease in stock price volatility would cause an approximate corresponding $60,000 increase or decrease to the Warrant Liability ($32,000 – December 31, 2015).

Note 5 - Inventories

Note 5 - Inventories	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. INVENTORIES Inventories are comprised of the following (in thousands): June 30, 2016 December 31, 201 5 $ $ Raw materials 808 1,083 Work in progress 543 328 Finished goods 844 408 2,195 1,819 The carrying value of inventory as of June 30, 2016 includes a write-down and a provision for expired, obsolete, and damaged inventory in the amount of $23,000 [December 31, 2015 - $51,000]. For the three and six month period ended June 30, 2016, inventory write-downs and obsolescence charges were $15,000 and $49 ,000 [2015 - $47 ,000 and $128,000].

Note 6 - Accounts Payable and A

Note 6 - Accounts Payable and Accrued Liabilities	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities comprise (in thousands): June 30, 2016 December 31, 201 5 $ $ Trade accounts payable 1,400 966 Employee related accounts payable and accrued liabilities 930 1,035 Royalties 425 325 Other accrued liabilities 1,038 971 3,793 3,297 Accounts payable and accrued liabilities include $118,000 [December 31, 2015 - $8,000] of additions to property, plant, and equipment and $476,000 [December 31, 2015 – nil] of deferred transaction costs as at June 30, 2016. These amounts have been excluded from cash generated from investing activities and cash used in operating activities respectively on the consolidated statements of cash flows for the six months ended June 30, 2016, as the cash had not been disbursed.

Note 7 - Term Loan

Note 7 - Term Loan	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Long-term Debt [Text Block]	7. TERM LOAN On February 11, 2014, the Company entered into a loan and security agreement with SVB providing for up to a US$2.5 million term loan. The loan is secured by substantially all of the assets of the Company. The loan included financial covenants that were later removed in an amendment (refer to discussion below). The loan also includes certain non-financial covenants as well as a subjective acceleration clause. Under the terms of the original loan agreement, the loan bears an interest rate of Wall Street Journal Prime Rate plus 2.5% annually. Interest only payments were made until October 1, 2014 at which time, 32 equal monthly installments of principal plus accrued interest started to be made. On December 15, 2014, the Company entered into an amendment to the original loan agreement with SVB. Under the amendment, SVB agreed to continue to advance the remaining outstanding principal of US$1.4 million for the same term and interest rate under the original agreement. In addition, SVB waived its rights in respect of certain breaches and removed any future financial covenants. Interest only payments were made until April 1, 2015, at which time, 26 equal monthly installments of principal plus accrued interest are being made through to maturity on May 1, 2017. In addition, the Company will pay an additional final payment of up to 4% of the outstanding principal advanced upon repayment. The loan contains a voluntary prepayment option whereby the principal amount can be prepaid in whole, or in part, for a fixed fee if a prepayment is made on or before December 15, 2016. In connection with the original loan and amendment discussed above, 107,701 warrants with exercise prices ranging from $1.00 to $1.831 per warrant and a term of 10 years were granted to SVB. These warrants were measured at their fair market value using the Black-Scholes model on the date of their grants and had a combined estimated fair market value of $113,000, which was recorded as a debt discount that is being amortized into income over the term of the loan using the effective interest method. In addition, there were $233,000 of fees related to the term loan that are also being amortized over the term of the loan using the effective interest method. Amortization of the deferred financing costs for the three and six month periods ended June 30, 2016 were $12,000 and $27,000 (2015 – $24,000 and $50,000) and amortization of the debt discount for the three and six month periods ended June 30, 2016 was $7,000 and $16,000 (2015 – $14,000 and $29,000). Both of these amounts are included in interest expense and amortization of deferred financing costs and debt discount on the consolidated statements of loss and comprehensive loss . The term loan is comprised of the following amounts (in thousands): June 30, 2016 December 31, 201 5 $ $ Current portion of term loan 748 868 Current portion of unamortized debt financing costs (18 ) (42 ) Current portion of unamortized debt discount (10 ) (25 ) Current portion of long-term debt, net debt discount 720 801 Long-term portion of term loan - 362 Long-term portion of unamortized debt financing costs - (3 ) Long-term portion of unamortized debt discount - (2 ) Long-term of long-term debt, net debt discount - 357 Total 720 1,158 Future principal payments for the term loan as of June 30, 2016, are as follows (in thousands): June 30, $ 2016 748 Total 748

Note 8 - Lease Inducements

Note 8 - Lease Inducements	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	8. LEASE INDUCEMENTS Lease agreements entered into by the Company for its offices provides for lease inducements to be provided by the landlord to the Company, which are summarized as follows (in thousands): June 30, 2016 December 31, 201 5 $ $ Current Portion Rent-free inducement [i] 54 54 Non-repayable leasehold improvement allowance [ii] 115 115 169 169 Repayable leasehold improvement allowance [iii] 543 514 Total Current Portion 712 683 Long-Term Portion Rent-free inducement [i] 303 330 Non-repayable leasehold improvement allowance [ii] 640 698 943 1,028 Repayable leasehold improvement allowance [iii] 4,415 4,694 Total Long-Term Portion 5,358 5,722 Total 6,070 6,405 The lease inducements disclosed on the consolidated balance sheets as a result of these benefits is comprised of the following: [i] In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization expense for the three and six month periods ended June 30, 2016 amounted to $14,000 and $27,000 [2015 - $13,000 and $27,000]. [ii] The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the three and six month periods ended June 30, 2016 amounted to $29,000 and $57,000 [2015 - $29 ,000 and $58 ,000]. [iii] The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and six month periods ended June 30, 2016 amounted to $127,000 and $250,000 [2015 - $114,000 and $224,000]. Interest payments for the three and six month periods ended June 30, 2016 amounted to $139,000 and $281,000 [2015 - $152,000 and $307,000]. To secure the lease, the Company is maintaining a security deposit with the landlord in the form of an irrevocable letter of credit in the amount of $317,000 collateralized by a term deposit with a market value of $317,000 that is presented as part of restricted deposits in the long-term asset section of the balance sheets. The face value of the letter of credit was reduced by 67% in March 2016 from its original face value due to the Company achieving an operating profit during the year ended December 31, 2015. The reduction of $584,000 is included in cash generated from investing activities in the consolidated statements of cash flows.

Note 9 - Share Capital and Addi

Note 9 - Share Capital and Additional Paid-in Capital	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9 . SHARE CAPITAL AND ADDITIONAL PAID-IN CAPITAL [a] Authorized - Unlimited common shares without par value. [b] Issued 2016 Private Placement On June 17, 2016, the Company closed the first tranche of a non-brokered private placement of 892,858 common shares at a price of U.S. $0.56 (the “Private Placement”) with a group of investment funds controlled by OrbiMed Advisors, LLC (“OrbiMed”), the Company’s majority shareholder. The net proceeds were $599,000 after deduction of $44,000 of financing costs. [c] Stock option plan At the Annual General Meeting held September 3, 2008, the Company’s shareholders approved a stock option plan (“2008 Plan”). Under the plan, the Company may grant options to purchase common shares in the Company to employees, directors, officers and consultants of the Company. The exercise price of the options is determined by the Board to be equal to the fair market value of the commons shares on the grant date. The Company estimates the fair value of options on the date of the grant. The options vest over the requisite service period in accordance with terms as determined by the Board, typically over four years. Stock options expire no later than ten years from the date of grant. At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders’ approved a change to the Company’s 2008 stock option plan permitting the maximum shares authorized to be issued under the plan to be up to 20% of the issued and outstanding common shares outstanding at any point in time. At the Annual General and Special Meeting held on June 13, 2016, the Company’s shareholders’ approved all unallocated options, rights and other entitlements under the 2008 Plan and the ability of the Company to continue granting options under the plan. Of the 2,183,453 stock options authorized for grant under the 2008 Plan as at June 30, 2016, options for 1,378,161 shares were outstanding and 805,292 stock options were available for future grant. The following assumptions were used to estimate the fair value of options granted during the six month period ended June 30, 2016, and 2015 using a Black-Scholes option-pricing model: Six Months Ended June 30, 201 6 201 5 Risk-free interest rates 1.04 % 1.31 % Expected dividend yield 0 % 0 % Expected life (in years) 5.7 5.8 Expected volatility 125 % 121 % Fair value per stock option $ 0.74 $ 0.67 The expected volatility reflects the assumption that the historical volatility of common stock of the Company over a period similar to the expected life of the options is indicative of future trends. The Company estimates the risk-free interest rate using the Bank of Canada bond yield with a remaining term equal to the expected life of the option. The Company uses the simplified method for estimating the stock option term for stock option grants during the six month period ended June 30, 2016 as the Company has determined that the stock options are “plain vanilla” and historical share option exercises do not apply as the vesting term and contractual lives have significantly changed from those stock options exercised previously. At June 30, 2016, the following stock options were outstanding: Range of Number of shares under option Weighted average remaining contractual life Weighted average exercise price Number of options currently exercisable Weighted average exercise price $ # (years) $ # $ 0.60 - 0.92 674,137 9.09 0.73 160,662 0.78 1.02 - 1.80 224,113 6.97 1.49 185,773 1.48 2.20 344,561 5.79 2.20 344,561 2.20 3.00 - 3.10 135,350 6.72 3.09 131,218 3.10 0.60 - 3.10 1,378,161 7.69 1.45 822,214 1.90 The options expire at various dates from April 2, 2022 to March 23, 2026. Stock option transactions and the number of stock options outstanding are summarized below: Number of optioned common shares Weighted average # $ Balance, December 31, 201 5 1,533,022 1.38 Options granted 42,000 0.85 Options expired (625 ) 6.80 Options forfeited (196,236 ) 0.80 Balance, June 30, 2016 1,378,161 1.45 [d] Restricted share unit plan At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new restricted share unit plan (“RSU Plan”). At the Annual General and Special Meeting held on June 13, 2016, the Company’s shareholders’ approved all unallocated entitlements under the RSU Plan and the ability of the Company to continue granting Restricted Share Units (“RSUs”) under the RSU Plan. Under the plan, the Company may grant RSUs to employees, directors, and eligible consultants which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of vested RSUs multiplied by the then current market value of the RSUs. The fair market value of the RSUs is determined based upon the number of RSUs granted and the quoted closing price of the Company’s stock on the trading day immediately preceding the date of determination. The duration of the vesting period and other vesting terms applicable to the grant of the RSUs shall be determined by the Board. Number Weighted average of RSUs exercise price # $ Balance, December 31, 2015 112,489 1.02 RSUs granted 118,527 0.85 RSUs converted to common shares (99,155 ) (0.98 ) Balance, June 30, 2016 131,861 0.89 The restricted share units that were granted during the six month period ended June 30, 2016 were to settle a director compensation liability that was recorded in accounts payable and accrued liabilities. The $100,000 liability has been excluded from the change in accounts payable and accrued liabilities on the consolidated statement of cash flows. Of the 272,931 RSUs authorized for grant under the RSU Plan as at June 30, 2016, 141,070 RSUs are available for grant. [e] Deferred share unit plan At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new non-employee director deferred share unit plan (“DSU Plan”). At the Annual General and Special Meeting held on June 13, 2016, the Company’s shareholders’ approved all unallocated entitlements under the DSU Plan and the ability of the Company to continue granting Deferred Share Units (“DSUs”) under the DSU Plan. A DSU is a right granted to non-employee directors which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of DSUs multiplied by the then current market value of the DSUs. The fair market value of the DSU’s is determined based upon the number of DSUs granted and the quoted price of the Company’s stock on the trading day immediately preceding the determination date. The duration of the vesting period and other vesting terms applicable to the grant of the DSU’s shall be determined by the Board. Number Weighted average of DSUs exercise price # $ Balance, December 31, 2015 - - DSUs granted 86,918 0.85 Balance, June 30 , 2016 86,918 0.85 The deferred share units that were granted during the six month period ended June 30, 2016 were to settle a director compensation liability that was recorded in accounts payable and accrued liabilities. The $74,000 liability has been excluded from the change in accounts payable and accrued liabilities on the consolidated statement of cash flows. Of the 272,931 DSUs authorized for grant under the DSU Plan as at June 30, 2016, 186,013 are available for grant. [f] Stock-based compensation The following table shows stock-based compensation allocated by type of cost (in thousands): Three Months Ended Six Months Ended 201 6 201 5 201 6 201 5 $ $ $ $ Cost of sales 7 9 17 17 Research and development 6 11 16 22 General and administrative 30 27 88 50 Sales and marketing 1 3 14 16 Total 44 50 135 105 As of June 30, 2016, the total unrecognized compensation related to stock options granted amounts to $323,000, which is expected to be recognized over a weighted average service period of 2.45 years. [g] Common share purchase warrants At June 30, 2016, there were 86,848,002 warrants outstanding to purchase shares of common stock, with expiry dates ranging from November 7, 2016 to December 15, 2024. Of the total 86,848,002 warrants outstanding, 86,103,744 warrants (the warrants related to the 2011 financing) entitle the holder thereof to purchase 1/20th of a common share of the Company at a price of $1.461 per whole common share; 636,557 warrants (the private placement warrants) entitle the holder thereof to purchase one common share of the Company at a price of $3.58 per common share; 52,796 warrants entitle the holder thereof to purchase one common share of the Company at a price of $1.831 per common share; and 54,905 warrants entitle the holder thereof to purchase one common share of the Company at a price of $1.00 per common share. There has been no common share purchase warrant transactions during the three months ended June 30, 2016. The estimated fair value of the warrants related to the 2011 financing is reassessed at each balance sheet date using the Black-Scholes option pricing model. The following assumptions were used to value the warrants on the following balance sheet dates: As at June 30, 2016 2015 Risk-free interest rates 0.52 % 0.49 % Expected dividend yield 0 % 0 % Expected life (in years) 0.5 1.5 Expected volatility 124 % 100 % Fair value of warrant $ 0.0112 $ 0.0156 [h] Earnings per common share Basic net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding using the treasury stock method. Dilutive potential common shares outstanding include outstanding warrants, stock options, restricted share units and deferred share units. 86,848,002 warrants, 1,378,161 stock options, 131,861 restricted share units, and 86,918 deferred share units have been excluded from the computation of diluted earnings per share for the three and six month periods ended June 30, 2016 as the Company has incurred a net loss during the periods and their inclusion would be anti-dilutive to the loss per share (2015 – 86,865,691 warrants, 1,333,835 stock options and 112,489 restricted share units were excluded).

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	10. RELATED PARTY TRANSACTIONS On June 17, 2016, the Company closed the Private Placement for common shares with a group of investment funds controlled by OrbiMed, the Company’s majority shareholder. The net proceeds were $599,000 after deduction of $44,000 of financing costs. The Company received US$1.28 million from Joinstar upon signing of the Technology Development Agreement and Collaboration Agreement. These upfront payments are being recognized into income over the expected development period and for the three and six month periods ended June 30, 2016, $56,000 and $169,000 was recognized (2015 – 246,000 and $515,000). These development fees are included under collaborative revenue in the consolidated statements of loss and comprehensive loss. The unrecognized portion of the development fees are included under deferred revenue on the consolidated balance sheet.

Note 11 - Commitments

Note 11 - Commitments	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Commitments Disclosure [Text Block]	11. COMMITMENTS [a] License agreements The Company entered into a non-exclusive license agreement, effective July 2005, as amended June 2008, to use and sublicense certain technology (“Technology”) for one of the Company’s cardiac tests. In consideration for these rights, the Company paid a non-refundable license issuance fee of $2.0 million in the first two years after execution of the agreement and is required to pay quarterly royalties on the sale of products that incorporate the Technology. For the three and six month periods ended June 30, 2016, the Company incurred an expense of $15,000 and $193,000 [2015 - $248,000 and $465,000] for royalties. Royalty and license fees incurred are included in cost of sales. [b] Supply agreement The Company entered into a supply agreement, effective September 2003 for certain reagents for the Company’s RAMP ® ® [c] Lease agreements [i] The Company entered into a long-term agreement to lease a single tenant 46,000 square foot facility to house all of the Company’s operations. Rent is payable from February 1, 2008 to January 31, 2023. The Company is required to pay the landlord total gross monthly payments of approximately $175,000, which is comprised of base rent, administrative and management fees, estimated property taxes and repayments of the repayable leasehold improvement allowance [note 8[iii]]. [ii] The Company has entered into a new lease agreement for new office space in Shanghai, China as of December 01, 2015 that expires on November 30, 2017. The Company is required to make monthly payments of approximately $5,000 for base rent and management fees under the new lease agreement. [iii] The Company has entered into operating leases for administrative equipment. For the three and six month periods ended June 30, 2016, $218,000 and $407,000 [2015 - $211,000 and $406,000] was incurred for expenses related to base rent, administrative and management fees and estimated property taxes offset by amortization of both the rent-free inducement [note 8[i]] and non-repayable leasehold improvement allowance [note 8[ii]]. These expenses are allocated to cost of sales, research and development, general and administrative, and sales and marketing expenses. [d] Purchase Commitments As at June 30, 2016, the Company has outstanding purchase commitments of $2.1 million to purchase inventory and capital equipment over the next five years of which $1.5 million will be completed within the next twelve months. [e ] Indemnification of directors and officers Under the Articles of the Company, applicable law and agreements with its directors and officers, the Company, in circumstances where the individual has acted legally, honestly and in good faith, may, or is required to indemnify its directors and officers against certain losses. The Company's liability in respect of the indemnities is not limited. The maximum potential of the future payments is unlimited. However, the Company maintains appropriate liability insurance that limits the exposure and enables the Company to recover any future amounts paid, less any deductible amounts pursuant to the terms of the respective policies, the amounts of which are not considered material. [f] Indemnification of third parties The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnifications generally require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims for damages arising from these transactions. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount that it could be required to pay. To date, the Company has not made any indemnification payments under such agreements and no amount has been accrued in these consolidated financial statements with respect to these indemnification obligations.

Note 12 - Segmented Information

Note 12 - Segmented Information	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	12. SEGMENTED INFORMATION The Company operates primarily in one business segment, the research, development, commercialization and distribution of diagnostic technologies, with primarily all of its assets and operations located in Canada. The Company’s revenues are generated from product sales primarily in Asia, the United States and Europe. Expenses are primarily incurred from purchases made from suppliers in Canada and the United States. Customers that represent a concentration risk are those whose outstanding receivable is 10% or greater than the total balance or those customers who represent 10% or greater of our total revenue. For the three month period ended June 30, 2016, $0.8 million (63%) in product sales were generated from four customers of which one customer represented 19%, one customer represented 18%, one customer represented 14%, and one customer represented 13% [2015 - $2.5 million (70%) from one customer]. For the six month period ended June 30, 2016, $1.9 million (55%) in product sales were generated from three customers of which one customer represents 31%, one customer represents 13%, and the other customer represents 11% [2015 - $4.8 million (71%) from one customer]. Sales attributable to a geographic area based upon the customer’s country of domicile. Sales in a country that represent 5% or more of total product sales, in to sales in Canada, are as follows (in thousands): Three Months Ended Six Months Ended 2016 2015 2016 2015 $ $ $ $ China 10 2,545 1,069 4,923 United States 418 432 738 686 Russia 227 176 430 338 Iran 173 151 324 342 Japan 159 79 267 162 Venezuela 85 - 129 43 Canada 1 17 5 24 Other 192 163 394 316 Total 1,265 3,563 3,356 6,834 Product sales by type of product were as follows (in thousands): Three Months Ended Six Months Ended 2016 2015 2016 2015 $ $ $ $ Cardiovascular 922 3,143 2,749 6,232 Infectious Diseases 36 1 91 50 Biodefense products 65 144 134 199 Environmental 242 275 382 353 Total 1,265 3,563 3,356 6,834

Note 13 - Comparative Figures

Note 13 - Comparative Figures	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Comparative Figures [Text Block]	13. COMPARATIVE FIGURES Certain comparative figures have been reclassified from the amounts previously reported to conform to the presentation adopted in the current year. As mentioned in Note 3, deferred financing costs have been reclassified from current and long term assets to the term loan in the liabilities section on the consolidated balance sheet.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Newly Adopted Accounting Pronouncements In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”). ASU 2015-03 was issued to simplify the presentation of debt issuance costs. The guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by these amendments. This guidance should be applied on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The adoption of this newly issued guidance resulted in the reclassification of the previously recorded Deferred Debt Financing Costs (both current and long term), which were previously included under the assets section of the consolidated balance sheet, as a deduction of the Term loan (both current and long term) on the consolidated balance sheet. Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (Topic 606) (“ASU 2014-09”), which supersedes the revenue recognition requirements in Accounting Standards Codification 605, “Revenue Recognition.” ASU 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts , including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. On July 9, 2015, the FASB decided to delay the effective date of the new standard by one year. ASU 2014-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. We are evaluating the impact of adopting this pronouncement. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” (Topic 330) (“ASU 2015-11”), which amends the guidelines for the measurement of inventory. Under the amendments, an entity should measure inventory valued using a first-in, first-out or average cost method at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company has not chosen early adoption for this ASU and is currently evaluating the impact of adopting this pronouncement. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 2015-40) (“ASU 2014-15”). ASU 2014-15 provides guidance to U.S. GAAP about management’s responsibility to evaluate whether there is a substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. This new rule requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles currently in the U.S. auditing standards. Specifically, ASU 2014-15 (1) defines the term substantial doubt, (2) requires an evaluation of every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires an express statement and other disclosures when substantial doubt is not alleviated, and (5) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This guidance is effective for annual periods ending after December 15, 2016 . In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires lessees to put most leases on their balance sheets as a liability for the obligation to make lease payments and as a right-of-use asset, but recognize expenses on the income statements in a manner similar to today’s accounting. The guidance also eliminates the current real estate-specific provisions for all entities. This guidance is effective for annual period beginning after December 15, 2018. Early adoption is permitted for all entities. The Company has not chosen early adoption for this ASU and is currently evaluating its effect on the Company’s consolidated financial statements.

Note 4 - Fair Value Measureme20

Note 4 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Fair Value, by Balance Sheet Grouping [Table Text Block]	Level 1 Level 2 Level 3 Total Liabilities $ $ $ $ Warrant Liability - - 964 964
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Balance at December 31, 201 5 Unrealized loss Exercise of Warrants Balance at June 30, 201 6 Warrant Liability 301 663 - 964
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	Valuation Technique Unobservable Input As at June 30, 201 6 As at December 31, 201 5 Warrant Liability Option Model Stock Price Volatility 124 % 128 %

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2016 December 31, 201 5 $ $ Raw materials 808 1,083 Work in progress 543 328 Finished goods 844 408 2,195 1,819

Note 6 - Accounts Payable and22

Note 6 - Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	June 30, 2016 December 31, 201 5 $ $ Trade accounts payable 1,400 966 Employee related accounts payable and accrued liabilities 930 1,035 Royalties 425 325 Other accrued liabilities 1,038 971 3,793 3,297

Note 7 - Term Loan (Tables)

Note 7 - Term Loan (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	June 30, 2016 December 31, 201 5 $ $ Current portion of term loan 748 868 Current portion of unamortized debt financing costs (18 ) (42 ) Current portion of unamortized debt discount (10 ) (25 ) Current portion of long-term debt, net debt discount 720 801 Long-term portion of term loan - 362 Long-term portion of unamortized debt financing costs - (3 ) Long-term portion of unamortized debt discount - (2 ) Long-term of long-term debt, net debt discount - 357 Total 720 1,158
Schedule of Maturities of Long-term Debt [Table Text Block]	June 30, $ 2016 748 Total 748

Note 8 - Lease Inducements (Tab

Note 8 - Lease Inducements (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Lease Inducements [Table Text Block]	June 30, 2016 December 31, 201 5 $ $ Current Portion Rent-free inducement [i] 54 54 Non-repayable leasehold improvement allowance [ii] 115 115 169 169 Repayable leasehold improvement allowance [iii] 543 514 Total Current Portion 712 683 Long-Term Portion Rent-free inducement [i] 303 330 Non-repayable leasehold improvement allowance [ii] 640 698 943 1,028 Repayable leasehold improvement allowance [iii] 4,415 4,694 Total Long-Term Portion 5,358 5,722 Total 6,070 6,405

Note 9 - Share Capital and Ad25

Note 9 - Share Capital and Additional Paid-in Capital (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six Months Ended June 30, 201 6 201 5 Risk-free interest rates 1.04 % 1.31 % Expected dividend yield 0 % 0 % Expected life (in years) 5.7 5.8 Expected volatility 125 % 121 % Fair value per stock option $ 0.74 $ 0.67
Schedule of Share-based Compensation, Activity [Table Text Block]	Range of Number of shares under option Weighted average remaining contractual life Weighted average exercise price Number of options currently exercisable Weighted average exercise price $ # (years) $ # $ 0.60 - 0.92 674,137 9.09 0.73 160,662 0.78 1.02 - 1.80 224,113 6.97 1.49 185,773 1.48 2.20 344,561 5.79 2.20 344,561 2.20 3.00 - 3.10 135,350 6.72 3.09 131,218 3.10 0.60 - 3.10 1,378,161 7.69 1.45 822,214 1.90
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of optioned common shares Weighted average # $ Balance, December 31, 201 5 1,533,022 1.38 Options granted 42,000 0.85 Options expired (625 ) 6.80 Options forfeited (196,236 ) 0.80 Balance, June 30, 2016 1,378,161 1.45
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	Number Weighted average of RSUs exercise price # $ Balance, December 31, 2015 112,489 1.02 RSUs granted 118,527 0.85 RSUs converted to common shares (99,155 ) (0.98 ) Balance, June 30, 2016 131,861 0.89 Number Weighted average of DSUs exercise price # $ Balance, December 31, 2015 - - DSUs granted 86,918 0.85 Balance, June 30 , 2016 86,918 0.85
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended Six Months Ended 201 6 201 5 201 6 201 5 $ $ $ $ Cost of sales 7 9 17 17 Research and development 6 11 16 22 General and administrative 30 27 88 50 Sales and marketing 1 3 14 16 Total 44 50 135 105
Estimated Fair Value Of Warrants Issued, Valuation Assumptions [Table Text Block]	As at June 30, 2016 2015 Risk-free interest rates 0.52 % 0.49 % Expected dividend yield 0 % 0 % Expected life (in years) 0.5 1.5 Expected volatility 124 % 100 % Fair value of warrant $ 0.0112 $ 0.0156

Note 12 - Segmented Informati26

Note 12 - Segmented Information (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Three Months Ended Six Months Ended 2016 2015 2016 2015 $ $ $ $ China 10 2,545 1,069 4,923 United States 418 432 738 686 Russia 227 176 430 338 Iran 173 151 324 342 Japan 159 79 267 162 Venezuela 85 - 129 43 Canada 1 17 5 24 Other 192 163 394 316 Total 1,265 3,563 3,356 6,834
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended Six Months Ended 2016 2015 2016 2015 $ $ $ $ Cardiovascular 922 3,143 2,749 6,232 Infectious Diseases 36 1 91 50 Biodefense products 65 144 134 199 Environmental 242 275 382 353 Total 1,265 3,563 3,356 6,834

Note 2 - Basis of Presentatio27

Note 2 - Basis of Presentation and Going Concern Uncertainty (Details Textual)	Jun. 17, 2016$ / sharesshares	Jun. 16, 2016USD ($)$ / sharesshares	Jun. 30, 2016CAD	Jun. 30, 2015CAD	Jun. 30, 2016CAD	Jun. 30, 2016USD ($)	Jun. 30, 2015CAD	Dec. 31, 2015CAD	Jun. 30, 2016USD ($)	Jun. 16, 2016CAD / shares	Dec. 31, 2014CAD
Warrant [Member]
Derivative Liability, Current			CAD 964,000		CAD 964,000
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member]
Concentration Risk, Percentage					31.00%	31.00%	79.00%
1077801 B.C. Ltd. [Member] | Response Biomedical Corp. [Member]
Business Acquisition, Share Price | CAD / shares										CAD 1.12
Percentage of Common Shareholders' Approval Required to Execute Sale of Stock		66.67%
Private Placement [Member] | Orbi Med [Member]
Share Price | $ / shares	$ 0.56
Stock Issued During Period, Shares, New Issues | shares	892,858
Stock Issued During Period, Value, New Issues | $		$ 500,000
Private Placement [Member] | Runda [Member]
Common Stock, Shares Subscribed but Unissued | shares		892,858
Common Stock, Value, Subscriptions | $		$ 500,000
Private Placement [Member]
Common Stock, Shares Subscribed but Unissued | shares		1,785,716
Share Price | $ / shares		$ 0.56
Common Stock, Value, Subscriptions | $		$ 1,000,000
Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Development Milestone, Remaining Six Months [Member]
Cash Proceeds from Technology Development Agreement | $						$ 3,000,000
Revenue Recognition, Milestone Method, Revenue Receivable | $									$ 800,000
Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Revenue Based Payments [Member]
Commercialization Period					5 years	5 years
Hangzhou Joinstar Biomedical Co. Ltd. [Member]
Supply Agreement, Eligible Royalty Revenue | $						$ 1,780,000
Net Income (Loss) Attributable to Parent			(1,322,000)	CAD (2,000)	CAD (2,571,000)		CAD (1,102,000)	CAD (150,000)
Cash and Cash Equivalents, Period Increase (Decrease)					(931,000)		(1,635,000)
Cash and Cash Equivalents, at Carrying Value			1,580,000	CAD 1,586,000	1,580,000		CAD 1,586,000	2,511,000			CAD 3,221,000
Retained Earnings (Accumulated Deficit)			(122,980,000)		(122,980,000)			(120,409,000)
Stockholders' Equity Attributable to Parent			(2,374,000)		(2,374,000)			(711,000)			CAD (894,000)
Working Capital Deficit			2,800,000		2,800,000
Derivative Liability, Current			964,000		964,000			CAD 301,000
Working Capital If Excluding Warrant Liability			CAD 1,800,000		1,800,000
Stock Issued During Period, Value, New Issues					CAD 599,000

Note 4 - Fair Value Measureme28

Note 4 - Fair Value Measurements (Details Textual) - CAD	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Warrant [Member]
Derivative Liability, Current	CAD 964,000
Increase (Decrease) in Stock Price Volatility	5.00%
Fair Value Inputs, Discount Rate	11.00%
Derivative Liability, Current	CAD 964,000	CAD 301,000
Fair Value Measurement, Liability, Impact of 5 Percent Change in Volatility	CAD 60,000	CAD 32,000

Note 4 - Financial Instrument C

Note 4 - Financial Instrument Carried at Fair Value (Details) - CAD CAD in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Current	CAD 964
Derivative Liability, Current	CAD 964	CAD 301

Note 4 - Changes in Fair Value

Note 4 - Changes in Fair Value of the Level 3 Financial Liabilities (Details) - CAD CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Warrant Liability, Beginning of Period			CAD 301
Warrant Liability, Unrealized Gain			663
Warrant Liability, End of Period	CAD 964		964
Fair Value, Inputs, Level 3 [Member]
Warrant Liability, End of Period	964		964
Warrant Liability, Beginning of Period			301
Warrant Liability, Unrealized Gain	223	CAD 150	663	CAD 95
Warrant Liability, End of Period	CAD 964		CAD 964

Note 4 - Quantitative Informati

Note 4 - Quantitative Information about Unobservable Inputs (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Warrant [Member]
Warrant Liability	124.00%	128.00%

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - CAD	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Expired and Damaged [Member]
Inventory Valuation Reserves	CAD 23,000		CAD 23,000		CAD 51,000
Inventory Write-down	CAD 15,000	CAD 47,000	CAD 49,000	CAD 128,000

Note 5 - Inventory (Details)

Note 5 - Inventory (Details) - CAD CAD in Thousands	Jun. 30, 2016	Dec. 31, 2015
Raw materials	CAD 808	CAD 1,083
Work in progress	543	328
Finished goods	844	408
Total	CAD 2,195	CAD 1,819

Note 6 - Accounts Payable and34

Note 6 - Accounts Payable and Accrued Liabilities (Details Textual) - CAD	Jun. 30, 2016	Dec. 31, 2015
Additions to PPE [Member]
Accrued Liabilities and Other Liabilities	CAD 118,000	CAD 8,000
Deferred Financing Costs [Member]
Accrued Liabilities and Other Liabilities	CAD 476,000	CAD 0

Note 6 - Accounts Payable and35

Note 6 - Accounts Payable and Accrued Liabilities (Details) - CAD CAD in Thousands	Jun. 30, 2016	Dec. 31, 2015
Trade accounts payable	CAD 1,400	CAD 966
Employee related accounts payable and accrued liabilities	930	1,035
Royalties	425	325
Other accrued liabilities	1,038	971
Accounts payable and accrued liabilities	CAD 3,793	CAD 3,297

Note 7 - Term Loan (Details Tex

Note 7 - Term Loan (Details Textual) CAD / shares in Units, $ in Millions	Feb. 11, 2014USD ($)	Jun. 30, 2016CADshares	Jun. 30, 2015CAD	Jun. 30, 2016CAD	Jun. 30, 2015CAD	Dec. 15, 2015CADCAD / sharesshares	Apr. 01, 2015	Dec. 15, 2014USD ($)
Silicon Valley Bank [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | CAD / shares						CAD 1
Silicon Valley Bank [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | CAD / shares						CAD 1.831
Silicon Valley Bank [Member]
Term Loan, Maximum Borrowing Capacity | $	$ 2.5
Debt Instrument, Basis Spread on Variable Rate	2.50%
Debt Instrument, Periodic Payment, Number of Installments	32						26
Debt Instrument, Face Amount | $								$ 1.4
Final Payment, Percentage of Principal							4.00%
Class of Warrant or Right, Issued During Period | shares						107,701
Fair Value Assumptions, Expected Term						10 years
Fair Value Of Warrant						CAD 113,000
Debt Issuance Costs, Net						CAD 233,000
Class of Warrant or Right, Issued During Period | shares		0
Amortization of Debt Issuance Costs		CAD 12,000	CAD 24,000	CAD 27,000	CAD 49,000
Amortization of Debt Discount (Premium)		CAD 7,000	CAD 14,000	CAD 16,000	CAD 29,000

Note 7 - Term Loan Components (

Note 7 - Term Loan Components (Details) - CAD CAD in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current portion of term loan	CAD 748	CAD 868
Current portion of unamortized debt financing costs	(18)	(42)
Current portion of unamortized debt discount	(10)	(25)
Current portion of long-term debt, net debt discount	720	801
Long-term portion of term loan		362
Long-term portion of unamortized debt financing costs		(3)
Long-term portion of unamortized debt discount		(2)
Long-term of long-term debt, net debt discount		357
Total	CAD 720	CAD 1,158

Note 7 - Future Principal Payme

Note 7 - Future Principal Payments for Term Loan (Details) - Term Loan [Member] CAD in Thousands	Jun. 30, 2016CAD
2,016	CAD 748
Total	CAD 748

Note 8 - Lease Inducements (Det

Note 8 - Lease Inducements (Details Textual)	Apr. 01, 2008CAD	Feb. 01, 2008CAD	Mar. 31, 2016	Jun. 30, 2016CAD	Jun. 30, 2015CAD	Jun. 30, 2015USD ($)	Jun. 30, 2016CAD	Jun. 30, 2016USD ($)	Jun. 30, 2015CAD	Jun. 30, 2015USD ($)	Dec. 31, 2015CAD
Lease Incentive One [Member]
Amortization Of Lease Incentives Lessee				CAD 14,000	CAD 13,000		CAD 27,000		CAD 27,000
Lease Incentive Two [Member]
Amortization Of Lease Incentives Lessee				29,000		$ 29,000		$ 57,000		$ 58,000
Allowance For Leasehold Improvement Nonpayable	CAD 1,700,000
Lease Incentive Three [Member] | Monthly [Member]
Allowance For Leasehold Improvement Repayable		CAD 89,000
Lease Incentive Three [Member]
Amortization Of Lease Incentives Lessee				127,000	114,000		250,000		224,000
Allowance For Leasehold Improvement Nonpayable	CAD 7,800,000
Interest Expense				139,000	152,000		281,000		307,000
Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity				317,000			317,000
Certificates of Deposit [Member]
Restricted Cash and Cash Equivalents, Noncurrent				317,000			317,000
Interest Expense				177,000	CAD 225,000		368,000		460,000
Restricted Cash and Cash Equivalents, Noncurrent				CAD 317,000			317,000				CAD 901,000
Face Value Reduction of Letter of Credit			67.00%
Increase (Decrease) in Restricted Cash							CAD (584,000)

Note 8 - Summary of Lease Induc

Note 8 - Summary of Lease Inducements (Details) - CAD CAD in Thousands		Jun. 30, 2016	Dec. 31, 2015
Rent Free Inducement [Member]
Lease Incentive Payable, Current	[1]	CAD 54	CAD 54
Lease Incentive Payable, Noncurrent	[1]	303	330
Repayable Leasehold Improvement Allowance [Member]
Lease Incentive Payable, Current	[2]	115	115
Lease Incentive Payable, Noncurrent	[2]	640	698
Lease Incentive Payable, Current		169	169
Repayable leasehold improvement allowance	[3]	543	514
Total Current Portion		712	683
Lease Incentive Payable, Noncurrent		943	1,028
Repayable leasehold improvement allowance	[3]	4,415	4,694
Total Long-Term Portion		5,358	5,722
Total		CAD 6,070	CAD 6,405
[1]	In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization expense for the three month period ended March 31, 2016 amounted to $14,000 [2015 - $14,000].
[2]	The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the three month period ended March 31, 2016 amounted to $29,000 [2015 - $29,000].
[3]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three month period ended March 31, 2016 amounted to $123,000 [2015 - $110,000]. Interest payments for the three month period ended March 31, 2016 amounted to $142,000 [2015 - $155,000].

Note 9 - Share Capital and Ad41

Note 9 - Share Capital and Additional Paid-in Capital (Details Textual)	Jun. 17, 2016CADshares	Sep. 03, 2008	Jun. 30, 2016CADCAD / sharesshares	Jun. 30, 2016CADCAD / sharesshares	Jun. 30, 2015shares	Jun. 17, 2016$ / shares	Jun. 16, 2016$ / shares	Dec. 31, 2015shares
Private Placement [Member] | Orbi Med [Member]
Stock Issued During Period, Shares, New Issues	892,858
Share Price | $ / shares						$ 0.56
Proceeds from Issuance of Common Stock | CAD	CAD 599,000
Payments of Stock Issuance Costs | CAD	CAD 44,000
Private Placement [Member] | Related to 2011 Financing [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | CAD / shares			CAD 1.461	CAD 1.461
Private Placement [Member] | Common Stock [Member]
Class of Warrant or Right, Outstanding			636,557	636,557
Class of Warrant or Right, Exercise Price of Warrants or Rights | CAD / shares			CAD 3.58	CAD 3.58
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1	1
Private Placement [Member]
Share Price | $ / shares							$ 0.56
Employee Stock Option [Member] | Stock Option Plan 2008 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			2,183,453	2,183,453
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			1,378,161	1,378,161	1,333,835
Restricted Stock Units (RSUs) [Member] | Accounts Payable and Accrued Liabilities [Member]
Stock Issued During Period, Value, Issued for Services | CAD				CAD 100,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			272,931	272,931
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			141,070	141,070
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			131,861	131,861	112,489
Deferred Share Unit Plan (DSUs) [Member] | Accounts Payable and Accrued Liabilities [Member]
Stock Issued During Period, Value, Issued for Services | CAD				CAD 74,000
Deferred Share Unit Plan (DSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			272,931	272,931
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			186,013	186,013
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			86,918	86,918
Stock Option Plan 2008 [Member]
Share-based Compensation Arrangement By Share-based Payment Award, Maximum Percentage Of Shares			20.00%	20.00%
Related to 2011 Financing [Member]
Class of Warrant or Right, Outstanding			86,103,744	86,103,744
Agent Warrants [Member] | Common Stock [Member]
Class of Warrant or Right, Outstanding			52,796	52,796
Class of Warrant or Right, Exercise Price of Warrants or Rights | CAD / shares			CAD 1.831	CAD 1.831
Silicon Valley Bank [Member]
Class of Warrant or Right, Outstanding			54,905	54,905
Class of Warrant or Right, Exercise Price of Warrants or Rights | CAD / shares			CAD 1	CAD 1
Common Stock [Member]
Stock Issued During Period, Shares, New Issues				892,858
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			86,848,002	86,848,002	86,865,691
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			1,378,161	1,378,161				1,533,022
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			805,292	805,292
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | CAD			CAD 323,000	CAD 323,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				2 years 164 days
Class of Warrant or Right, Outstanding			86,848,002	86,848,002
Class of Warrant or Right, Issued During Period			0
Class Of Warrant Or Right Expired During Period			0

Note 9 - Share-based Payment Aw

Note 9 - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - CAD / shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Risk-free interest rates	1.04%	1.31%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	5 years 255 days	5 years 292 days
Expected volatility	125.00%	121.00%
Fair value per stock option (in Canadian Dollar per share)	CAD 0.74	CAD 0.67

Note 9 - Stock Options, Outstan

Note 9 - Stock Options, Outstanding (Details)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Range One [Member]
Lower exercise price (in dollars per share)	$ 0.60
Upper exercise price (in dollars per share)	$ 0.92
Number of shares under option (in shares) | shares	674,137
Weighted average remaining contractual life	9 years 32 days
Weighted average exercise price, options outstanding (in dollars per share)	$ 0.73
Number of options currently exercisable (in shares) | shares	160,662
Weighted average exercise price, options exercisable (in dollars per share)	$ 0.78
Range Two [Member]
Lower exercise price (in dollars per share)	1.02
Upper exercise price (in dollars per share)	$ 1.80
Number of shares under option (in shares) | shares	224,113
Weighted average remaining contractual life	6 years 354 days
Weighted average exercise price, options outstanding (in dollars per share)	$ 1.49
Number of options currently exercisable (in shares) | shares	185,773
Weighted average exercise price, options exercisable (in dollars per share)	$ 1.48
Range Three [Member]
Number of shares under option (in shares) | shares	344,561
Weighted average remaining contractual life	5 years 288 days
Weighted average exercise price, options outstanding (in dollars per share)	$ 2.20
Number of options currently exercisable (in shares) | shares	344,561
Weighted average exercise price, options exercisable (in dollars per share)	$ 2.20
Range Four [Member]
Lower exercise price (in dollars per share)	3
Upper exercise price (in dollars per share)	$ 3.10
Number of shares under option (in shares) | shares	135,350
Weighted average remaining contractual life	6 years 262 days
Weighted average exercise price, options outstanding (in dollars per share)	$ 3.09
Number of options currently exercisable (in shares) | shares	131,218
Weighted average exercise price, options exercisable (in dollars per share)	$ 3.10
Lower exercise price (in dollars per share)	0.60
Upper exercise price (in dollars per share)	$ 3.10
Number of shares under option (in shares) | shares	1,378,161
Weighted average remaining contractual life	7 years 251 days
Weighted average exercise price, options outstanding (in dollars per share)	$ 1.45
Number of options currently exercisable (in shares) | shares	822,214
Weighted average exercise price, options exercisable (in dollars per share)	$ 1.90

Note 9 - Stock Options, Activit

Note 9 - Stock Options, Activity (Details)	6 Months Ended
	Jun. 30, 2016CAD / sharesshares
Balance (in shares) | shares	1,533,022
Balance (in Canadian Dollar per share) | CAD / shares	CAD 1.38
Options granted (in shares) | shares	42,000
Options granted (in Canadian Dollar per share) | CAD / shares	CAD 0.85
Options expired (in shares) | shares	(625)
Options expired (in Canadian Dollar per share) | CAD / shares	CAD 6.80
Options forfeited (in shares) | shares	(196,236)
Options forfeited (in Canadian Dollar per share) | CAD / shares	CAD 0.80
Balance (in shares) | shares	1,378,161
Balance (in Canadian Dollar per share) | CAD / shares	CAD 1.45

Note 9 - Restricted Share Unit

Note 9 - Restricted Share Unit Plan (Details)	6 Months Ended
	Jun. 30, 2016CAD / sharesshares
Restricted Stock Units (RSUs) [Member]
Balance (in shares) | shares	112,489
Balance (in Canadian Dollar per share) | CAD / shares	CAD 1.02
Granted in period (in shares) | shares	118,527
Granted in period (in Canadian Dollar per share) | CAD / shares	CAD 0.85
Balance (in shares) | shares	131,861
Balance (in Canadian Dollar per share) | CAD / shares	CAD 0.89
Deferred Share Unit Plan (DSUs) [Member]
Balance (in shares) | shares
Balance (in Canadian Dollar per share) | CAD / shares
Granted in period (in shares) | shares	86,918
Granted in period (in Canadian Dollar per share) | CAD / shares	CAD 0.85
Balance (in shares) | shares	86,918
Balance (in Canadian Dollar per share) | CAD / shares	CAD 0.85
RSUs converted to common shares (in shares) | shares	(99,155)
RSUs converted to common shares (in Canadian Dollar per share) | CAD / shares	CAD (0.98)

Note 9 - Allocation of Stock-ba

Note 9 - Allocation of Stock-based Compensation, by Type of Cost (Details) - CAD CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Cost of Sales [Member]
Share based compensation expense	CAD 7	CAD 9	CAD 17	CAD 17
Research and Development Expense [Member]
Share based compensation expense	6	11	16	22
General and Administrative Expense [Member]
Share based compensation expense	30	27	88	50
Selling and Marketing Expense [Member]
Share based compensation expense	1	3	14	16
Share based compensation expense	CAD 44	CAD 50	CAD 135	CAD 105

Note 9 - Estimated Fair Value o

Note 9 - Estimated Fair Value of Warrants Issued (Details) - Warrant [Member] - CAD	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Risk-free interest rates	0.52%	0.49%
Expected dividend yield	0.00%	0.00%
Fair Value Assumptions, Expected Term	182 days	1 year 182 days
Expected volatility	124.00%	100.00%
Fair Value Of Warrant	CAD 0.0112	CAD 0.0156

Note 10 - Related Party Trans48

Note 10 - Related Party Transactions (Details Textual) $ in Thousands	Jun. 17, 2016CAD	Jun. 30, 2016CAD	Jun. 30, 2015CAD	Jun. 30, 2016CAD	Jun. 30, 2015CAD	Dec. 31, 2015USD ($)
Orbi Med [Member] | Private Placement [Member]
Proceeds from Issuance of Common Stock	CAD 599,000
Payments of Stock Issuance Costs	CAD 44,000
Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Upfront Payment [Member]
Cash Proceeds from Technology Development Agreement | $						$ 1,280
Contracts Revenue		CAD 56,000	CAD 246,000	CAD 169,000	CAD 515,000
Contracts Revenue		CAD 56,000	CAD 703,000	CAD 169,000	CAD 972,000

Note 11 - Commitments (Details

Note 11 - Commitments (Details Textual)	Dec. 01, 2015CAD	Sep. 30, 2003	Jun. 30, 2016CAD	Jun. 30, 2015CAD	Jun. 30, 2016CAD	Jun. 30, 2015CAD	Jun. 30, 2007CAD	Dec. 31, 2015CADft²
Developed Technology Rights [Member]
Royalty Expense			CAD 15,000	CAD 248,000	CAD 193,000	CAD 465,000
West Nile Virus [Member]
Royalty Expense			20,000	27,000	34,000	35,000
Royalty Expense, Percentage of Revenue		10.00%
Operation Facility [Member]
Area of Real Estate Property | ft²								46,000
Operating Lease, Monthly Payments								CAD 175,000
Office in China [Member]
Operating Lease, Monthly Payments	CAD 5,000
Royalty Expense							CAD 2,000,000
Operating Leases, Rent Expense, Net			218,000	CAD 211,000	407,000	CAD 406,000
Purchase Obligation			2,100,000		2,100,000
Purchase Obligation, Due in Next Twelve Months			CAD 1,500,000		CAD 1,500,000

Note 12 - Segmented Informati50

Note 12 - Segmented Information (Details Textual) - Customer Concentration Risk [Member] - Sales Revenue, Goods, Net [Member] - CAD CAD in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Four Customers [Member]
Revenues	CAD 0.8
Concentration Risk, Percentage	63.00%
Customer One [Member]
Concentration Risk, Percentage	19.00%		31.00%
Customer Two [Member]
Concentration Risk, Percentage	18.00%		13.00%
Customer Three [Member]
Concentration Risk, Percentage	14.00%		11.00%
Customer Four [Member]
Concentration Risk, Percentage	13.00%
One Customer [Member]
Revenues		CAD 2.5		CAD 4.8
Concentration Risk, Percentage		70.00%		71.00%
Three Customers [Member]
Revenues			CAD 1.9
Concentration Risk, Percentage			55.00%
Concentration Risk, Percentage			31.00%	79.00%

Note 12 - Product Sales by Cust

Note 12 - Product Sales by Customer Location (Details) - CAD CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
CHINA
Product sales	CAD 10	CAD 2,545	CAD 1,069	CAD 4,923
UNITED STATES
Product sales	418	432	738	686
RUSSIAN FEDERATION
Product sales	227	176	430	338
IRAN, ISLAMIC REPUBLIC OF
Product sales	173	151	324	342
JAPAN
Product sales	159	79	267	162
VENEZUELA
Product sales	85		129	43
CANADA
Product sales	1	17	5	24
Segment, Geographical, Groups Of Countries, Group Three [Member]
Product sales	192	163	394	316
Product sales	CAD 1,265	CAD 3,563	CAD 3,356	CAD 6,834

Note 12 - Product Sales by Type

Note 12 - Product Sales by Type of Product (Details) - CAD CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Cardiovascular [Member]
Product sales	CAD 922	CAD 3,143	CAD 2,749	CAD 6,232
Infectious Diseases [Member]
Product sales	36	1	91	50
Biodefense Products [Member]
Product sales	65	144	134	199
West Nile Virus [Member]
Product sales	242	275	382	353
Product sales	CAD 1,265	CAD 3,563	CAD 3,356	CAD 6,834